Through whole-genome chromosomal abnormality testing of miscarriage tissue, amniotic fluid, single cells, and tumor tissue, the risk of early miscarriage can be effectively reduced. Additionally, the clinical pregnancy rate and live birth rate of in vitro fertilization (IVF) treatment can be improved, the incidence of children born with chromosomal defects can be decreased, and the pathogenic causes and disease progression related to abnormal tumor fragments can be identified
High efficiency and accuracy
fast and economical
Widely applicable
Population undergoing assisted reproduction
Elderly individuals, those at high risk in prenatal screening, and individuals with abnormal ultrasound findings
Families and children with genetic diseases: diagnosis of children with growth, intellectual, or developmental disorders and family verification
Tumor patients: solid tumor patients requiring precise diagnosis to guide targeted drug use
Investigation of the causes of miscarriage
Assist in diagnosing the causes of miscarriage
Improve the success rate of assisted reproduction
Assist in diagnosing children with growth, intellectual, or developmental disorders
sample collection
DNA extraction
library preparation
sequencing
data analysis
Result verification and release
7 working days after receiving qualified samples.